RxDoctor Payments Data

Erica Yates, MD

Family Medicine · Corinth, MSNPI 1306869375

Payments from drug & device makers

$8,914in general payments, 2019–2025

Across 577 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$787
  • Amgen$580
  • Lilly USA, LLC$480
  • GSK$455
  • Novo Nordisk$399
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$8,914100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)110$1,395
Pfizer59$787
Amgen39$580
Lilly USA, LLC41$480
GSK26$455
Novo Nordisk30$399
Otsuka America Pharmaceutical, Inc.17$340
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$315
Astellas Pharma US Inc16$297
Johnson & Johnson20$296
Takeda Pharmaceuticals U.S.A., Inc.20$283
AstraZeneca14$282
Esperion Therapeutics, Inc.9$218
Bayer12$201
Amarin Pharma, Inc.12$185
Biohaven Pharmaceutical Holding Company Ltd.10$166
Biohaven Pharmaceuticals, Inc.10$153
Supernus Pharmaceuticals, Inc.3$152
Abbott7$143
Boehringer Ingelheim8$138
Ironwood Pharmaceuticals, Inc9$133
Sanofi-aventis U.S. LLC9$130
Lundbeck LLC6$125
Novartis4$101
Electromed, Inc.5$91
Axsome Therapeutics, Inc.4$83
Corcept Therapeutics4$81
UCB, Inc.3$72
Kowa Pharmaceuticals America, Inc.3$70
Merck4$63
Daiichi Sankyo Inc.3$56
E.r. Squibb & Sons, L.L.C.4$55
Mylan Specialty L.p.3$43
Exact Sciences3$43
Nestle Healthcare Nutrition Inc.2$36
Sumitomo Pharma America, Inc.2$36
Arbor Pharmaceuticals, Inc.2$35
Dexcom, Inc.2$33
Corium, LLC1$30
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$27
Shire North American Group Inc2$27
Boston Scientific1$26
Upsher-smith Laboratories LLC2$26
Ardelyx, Inc.1$23
Xeris Pharmaceuticals, Inc.1$23
Phathom Pharmaceuticals, Inc.1$18
Medtronic1$18
Redhill Biopharma Inc.1$16
GRT US Holding, Inc.1$16
Avanir Pharmaceuticals, Inc.1$16
Bausch Health US, LLC1$15
Tris Pharma Inc1$15
Idorsia Pharmaceuticals US Inc1$15
Amneal Pharmaceuticals LLC1$13
Genentech USA, Inc.1$13
Adlon Therapeutics L.p.1$13
Teva Pharmaceuticals USA, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,914 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$250,741
Medicare patients
457
Services billed
7,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol210$187,257
MounjaroTirzepatide151$176,797
OzempicSemaglutide152$176,730
RexultiBrexpiprazole55$115,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter129$88,781
LinzessLinaclotide52$59,342
EliquisApixaban50$45,789
JardianceEmpagliflozin36$36,826
VascepaIcosapent Ethyl71$34,700
XareltoRivaroxaban29$34,127
KerendiaFinerenone22$24,379
RybelsusSemaglutide21$23,140
MyrbetriqMirabegron24$20,006
UbrelvyUbrogepant13$19,748
JanuviaSitagliptin Phosphate17$18,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$282$205,743243 claims
Novo NordiskOzempic, Rybelsus$399$199,870173 claims
Lilly USA, LLCMounjaro, Trulicity$480$186,858162 claims
Otsuka America Pharmaceutical, Inc.Rexulti$340$115,47955 claims
GSKTrelegy Ellipta$455$88,781129 claims
AbbVieLinzess, Ubrelvy, Synthroid$1,395$81,815113 claims
PfizerEliquis, Premarin$787$48,78663 claims
Boehringer IngelheimJardiance$138$36,82636 claims
Johnson & JohnsonXarelto$296$34,12729 claims
BayerKerendia$201$24,37922 claims
Astellas Pharma US IncMyrbetriq$297$20,00624 claims
MerckJanuvia$63$18,90417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Corinth

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →